Approval · Notice of Compliance 14939 · 2013
PREGABALIN: Notice of Compliance 14939
Issued November 22, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14939
- Date
- November 22, 2013
- Company
- Alembic Pharmaceuticals LimitedVadodara, Gujarat, India
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Analgesic agent
- Canadian reference product
- LYRICA (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PREGABALIN | 02416689 | Approved |
| PREGABALIN | 02416697 | Approved |
| PREGABALIN | 02416700 | Approved |
| PREGABALIN | 02416719 | Approved |
| PREGABALIN | 02416727 | Approved |
| PREGABALIN | 02416735 | Approved |
| PREGABALIN | 02416743 | Approved |
| PREGABALIN | 02416751 | Approved |
Medicinal ingredients
- PREGABALIN 25 MG per CAP
- PREGABALIN 50 MG per CAP
- PREGABALIN 75 MG per CAP
- PREGABALIN 100 MG per CAP
- PREGABALIN 150 MG per CAP
- PREGABALIN 200 MG per CAP
- PREGABALIN 225 MG per CAP
- PREGABALIN 300 MG per CAP